FDA Seeks Risk-Based Inspection Program

November 2, 2003

Jill Wechsler

Jill Wechsler

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Pharmaceutical Technology, Pharmaceutical Technology-11-02-2003, Volume 27, Issue 11

FDA's new policies intend to make GMP inspections more efficient and apply to stricter rules to high-risk products and processes.

Related Content:

Regulatory WatchPharmaceutical Technology-11-02-2003

FDA Documents Achievements and Plans for Future

FDA Inspection Shutdown Increasingly Delays Approvals

Pandemic Control to Shape Biopharma in 2021